In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Logicbio Therapeutics Inc (LOGC), with a price target of $20. The company’s shares closed yesterday at $13.44.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.8% and a 50.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Iovance Biotherapeutics Inc, and Catalyst Biosciences Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Logicbio Therapeutics Inc.
See today’s analyst top recommended stocks >>
Based on Logicbio Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $7.06 million. In comparison, last year the company had a GAAP net loss of $1.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene.
